ReviewCurrent rheumatology reports2020
Treatment of Axial Spondyloarthritis: What Does the Future Hold?
Review in Current rheumatology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Correlates of physical activity in adults with spondyloarthritis and rheumatoid arthritis: a systematic review.Rheumatology international · 2022Pooled it
- Wearables for Measuring the Physical Activity and Sedentary Behavior of Patients With Axial Spondyloarthritis: Systematic Review.JMIR mHealth and uHealth · 2022Pooled it
- Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis.BMC pharmacology & toxicology · 2025Trial
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.Annals of the rheumatic diseases · 2021Trial
- Multi-habitat radiomics on T2-FS MRI for identifying spatial patterns of axial spondyloarthritis-associated bone marrow edema.Clinical rheumatology · 2026Article
- Biologics reduced infections in ankylosing spondylitis and psoriatic arthritis under immunosuppressants.Journal of the Chinese Medical Association : JCMA · 2026Article
- Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.EULAR rheumatology open · 2026Article
- Sex-based differences in bDMARD initiation and persistence in spondyloarthritis: a 17-year follow-up study from the REGISPON-3 registry.Rheumatology (Oxford, England) · 2026Observational
- Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitis.International journal of clinical pharmacology and therapeutics · 2026Article
- Assessing the Quality of AI Responses to Patient Concerns About Axial Spondyloarthritis: Delphi-Based Evaluation.JMIR AI · 2026Article
- Erosive costovertebral joint arthritis as a novel feature of ankylosing spondylitis.Quantitative imaging in medicine and surgery · 2025Article
- Biomarkers of Inflammation and Radiographic Progression in Axial Spondyloarthritis: A Clinical Evaluation of Leptin, Adiponectin, TNF-α, and IL-17A.Journal of clinical medicine · 2025Article
- Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial.Rheumatology and therapy · 2025Article
- Cardiovascular comorbidities in spondyloarthritis.Clinical rheumatology · 2023Review
- Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis.Journal of patient-reported outcomes · 2022Article
- Searching for New Genetic Biomarkers of Axial Spondyloarthritis.Journal of clinical medicine · 2022Article
- [Spondyloarthritis in childhood and adulthood].Zeitschrift fur Rheumatologie · 2022Review
- Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry.ACR open rheumatology · 2022Article
- Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA.Therapeutic advances in musculoskeletal disease · 2022Article
- Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis.Annals of the rheumatic diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo provide a summary of the recent and expected developments related to the treatment of axial spondyloarthritis. RECENT
findingsAn increasing number of interleukin-17 blocking agents show efficacy in axial spondyloarthritis including both non-radiographic and radiographic forms. Janus kinase inhibitors showed promising results in phase II studies in radiographic axial spondyloarthritis and have, therefore, a potential to become a therapeutic option in this indication in the future. Inhibition of structural damage progression in axial spondyloarthritis seems to be possible in the case of effective and early anti-inflammatory treatment, although there are still open questions related to particular drug classes. Despite major advances in the field and growing therapeutic options, there are still many open questions related to the optimized treatment strategies and to the individual choice of a drug in axial spondyloarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.